Elekta ABEKTAF 79 Days Payable is 53.81 as of Apr. 2026, which is 2% below its 10-year median of 54.85. GuruFocus rates EKTAF with a GF Score™ of 79/100 and a GF Value™ of $5.78 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Elekta AB ranks worse than 59.75% on this metric.
Elekta AB's average Accounts Payable for the
three
months ended in Apr. 2026 was $183 Mil. Elekta AB's Cost of Goods Sold for the
three
months ended in Apr. 2026 was $311 Mil.
Hence, Elekta AB's Days Payable for the
three
months ended in Apr. 2026 was 53.81.
The historical rank and industry rank for Elekta AB's Days Payable or its related term are showing as below:
EKTAF'
s Days Payable Range Over the Past 10 Years
Min: 45.69 Med: 54.85 Max: 64.76
Current: 58.87
During the past 13 years, Elekta AB's highest Days Payable was 64.76. The lowest was 45.69. And the median was 54.85.
EKTAF's Days Payable is ranked worse than 59.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs EKTAF: 58.87
Elekta AB's Days Payable
increased
from Apr. 2025 (47.17) to Apr. 2026 (53.81).
It may suggest that Elekta ABdelayed paying its suppliers.
Elekta AB Days Payable Related Terms
Elekta AB Days Payable Historical Data
* Premium members only.
The historical data trend for Elekta AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Elekta AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Elekta AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Elekta AB's Days Payable for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAF) has a Days Payable of 53.81 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elekta AB and its competitors. This is near median its historical median of 54.85. Over the past decade, Elekta AB's Days Payable has ranged from 45.69 to 64.76. According to the industry distribution chart, Elekta AB ranks #475 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 59.7%.
Is Elekta AB's Days Payable too high?
Elekta AB's current Days Payable of 53.81 is near median its 10-year median of 54.85. Over the past 10 years, this metric has ranged from a low of 45.69 to a high of 64.76. The Medical Devices & Instruments industry median Days Payable is 68.07. Elekta AB's value of 53.81 is 20.9% below this industry median. Based on the distribution chart, Elekta AB ranks #475 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Elekta AB has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #475 out of 795 companies for Days Payable. This places Elekta AB in the lower half of its industry. The industry median Days Payable is 68.07. Elekta AB's value of 53.81 is 20.9% below this benchmark. Historically, Elekta AB's own Days Payable has ranged from 45.69 to 64.76 over the past decade. While the company's 10-year median is 54.85 vs. the industry median of 68.07, Elekta AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elekta AB's current Days Payable of 53.81 is 20.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elekta AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current Days Payable is 53.81, which is near median its own 10-year median of 54.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.78, compared to a current price of $5.04 — trading 12.8% below its estimated fair value. The current Days Payable is 53.81, which is near median its 10-year median of 54.85 and 20.9% below the Medical Devices & Instruments industry median of 68.07. Elekta AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Elekta AB (EKTAF), the current Days Payable is 53.81 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAF) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $5.04 is trading 12.8% below its estimated GF Value™ of $5.78.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAF:
Days Payable: 53.81 (near median its 10-year median of 54.85)
GF Value™: $5.78 vs. price of $5.04 (12.8% below fair value)
Industry Position: 20.9% below the Medical Devices & Instruments median (#475 of 795)
No single metric tells the full story. See the EKTAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
79GF Score
Get the complete analysis for EKTAF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAF has been successfully added to your 
